NCT04318327: Phase 1 - BCMA-directed CAR-T Cell Therapy in Adult Patients With RRMM
Updated: Feb 21
NCT04318327: Phase 1 - BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR) and manufactured with a new process. CAR-T cells will be investigated as a single agent in relapsed/refractory multiple myeloma
Biological:
PHE885
Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04318327
Official Title: Phase I, Open Label, Study of B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
First Posted : March 23, 2020
Click here for details on ClinicalTrials.gov
Autologous Anti-BCMA CAR T-cells PHE885 (Code C174124)
Autologous Anti-BCMA CAR T-cells PHE885
Autologous BCMA-specific CAR T-cells PHE885
BCMA-directed Autologous CAR-T Cells PHE885
PHE 885
PHE-885
PHE885
Autologous Anti-BCMA CAR T-cells PHE885
- Illinois: University of Chicago
- Massachusetts: Massachusetts General Hospital Boston
- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston
3864 Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-ChargeTM Platform
Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Clinical: Poster III
Hematology Disease Topics & Pathways:
Biological, Adults, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, Myeloid Malignancies, Study Population
Monday, December 13, 2021, 6:00 PM-8:00 PM
Click here for details
Locations
United States, Illinois
United States, Massachusetts
United States, Wisconsin